|
|
||||||||







* Center for Infection and Immunity Amsterdam,
Center for Experimental and Molecular Medicine,
Department for Pathology, and
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Platelet-activating factor (PAF)3 is a phospholipid that exerts various immunomodulatory actions during host defense against bacterial infections, including stimulation and degranulation of granulocytes, monocytes, and macrophages, the release of cytokines and toxic oxygen metabolites and facilitation of phagocytosis, killing, and cell adhesion (5, 6). PAF is produced mainly by neutrophils, macrophages, platelets, and endothelial cells (5, 6) and its biological activity is mediated through a G protein-linked receptor (PAF receptor, PAFR) that is expressed on different cell types, including neutrophils, macrophages, monocytes, and epithelial cells (7).
Previous studies have suggested a possible dual role of the PAFR during bacterial pneumonia that at least in part may depend on the causing pathogen. On one hand, PAF and its receptor may improve the ability of the host to deal with infections by facilitating phagocytosis and killing of engulfed microorganisms (8, 9, 10). In contrast, PAFR activation may underlie the tissue injury in the lungs (11, 12, 13). In addition, the PAFR can bind phosphorylcholine, which is not only a biologically important component of its natural ligand PAF but also part of the cell wall of a number of respiratory pathogens, including Streptococcus pneumoniae (14, 15) and Haemophilus influenzae (16); in the case of pneumococcal pneumonia, the interaction between phosphorylcholine and the PAFR facilitates bacterial invasion (17, 18), whereas it does not impact on host defense during H. influenzae pneumonia (19). Lung injury associated with P. aeruginosa infection results from both the direct destructive effects of the bacterium on the lung parenchyma as well as from excessive host immune responses (2). Despite its potential impact on the host response, the role of endogenous PAFR in the pathogenesis of Pseudomonas pneumonia and the ensuing sepsis syndrome has not been investigated so far. By using PAFR- deficient mice, we here show for the first time that PAFR contributes to host defense against P. aeruginosa pneumonia and sepsis.
| Materials and Methods |
|---|
|
|
|---|
Ten- to 12-wk-old male mice with a targeted deletion in the gene for pafr, resulting in a complete deficiency of PAFR (PAFR–/– mice), were generated as previously described (20) and backcrossed seven times to a C57BL/6 background. Wild-type (Wt) C57BL/6 mice were obtained from Harlan Sprague Dawley. The Institutional Animal Care and Use Committee of the Academic Medical Center, University of Amsterdam, approved all experiments.
Induction of pneumonia
P. aeruginosa pneumonia was induced as described previously (21). In brief, P. aeruginosa (strain PA01), grown to mid-logarithmic phase in Luria-Bertani, was harvested by centrifugation at 3400 x g for 15 min. After washing in pyrogen-free 0.9% NaCl (2x) and suspension of the bacteria in 10 ml of 0.9% NaCl, the number of bacteria was determined by serial dilution in sterile isotonic saline and cultured on blood agar plates. Mice were lightly anesthetized by inhalation of isoflurane (Abbott Laboratories), after which 50 µl of the bacterial solution, containing 108 (or in one experiment 107) CFUs was administered intranasally. After 6 h, mice were anesthetized with ketamine (Eurovet Animal Health) and medetomidine (Pfizer Animal Health). The 6-h time point was chosen because we and others have previously shown that it provides representative information about the growth of Pseudomonas in murine lungs and the ensuing inflammatory response (21, 22, 23, 24). In one experiment, the 24-h time point was used. Additionally, in a separate survival study mice were infected with 108 CFUs.
Preparation of blood samples and organ homogenates
Blood was collected from the vena cava inferior in heparin-containing tubes and centrifuged at 1500 x g for 10 min, after which plasma was collected and frozen at –20°C until assayed. The lungs were removed and processed as described previously (25, 26, 27). Lung weight was expressed as milligram of lung per gram of mouse to obtain relative organ weight. Lungs, liver, and spleen were harvested and homogenized at 4°C in 4 vol of sterile isotonic saline with a tissue homogenizer (Biospect Products) that was carefully cleaned and disinfected with 70% ethanol after each homogenization. Serial 10-fold dilutions in sterile saline were made from these homogenates, blood, and bronchoalveolar lavage fluid (BALF) (see below) and 50-µl volumes were plated onto sheep blood agar plates and incubated at 37°C and 5% CO2. CFUs were counted after 24 h. For cytokine, chemokine and myeloperoxidase (MPO) measurements, lung homogenates were lysed in 1 volume of lysis buffer (300 mM NaCl, 15 mM Tris [tris(hydroxymethyl)aminomethane], 2 mM MgCl2, 2 mM Triton X-100, pepstatin A, leupeptin, and aprotinin (20 ng/ml), pH 7.4) on ice for 30 min and centrifuged at 1500 x g at 4°C for 10 min. The supernatants were frozen at –20°C until assayed.
Bronchoalveolar lavage
In separate mice not used for pathology or preparation of lung homogenates, the trachea was exposed through a midline incision and cannulated with a sterile 22-gauge Abbocath-T catheter (Abbott Laboratories). Bilateral bronchoalveolar lavage was performed by instilling two 0.5-ml aliquots of sterile isotonic saline. In brief, 0.9–1 ml of lavage fluid was retrieved per mouse.
Phagocytosis assay
Phagocytosis of P. aeruginosa by neutrophils was determined as previously described (28, 29) with minor modifications. P. aeruginosa was heat killed by incubation at 65°C for 1 h and labeled with 0.2 mg/ml FITC (Sigma-Aldrich) in 0.1 M NaHCO3 (pH 9.0) for 1 h at 37°C. Fifty microliters of whole blood was incubated with 10 µl of heat-killed FITC-labeled P. aeruginosa (equivalent to 1 x 107 CFUs). After incubation for 0, 30, and 60 min at 37 and 4°C, phagocytosis was stopped by immediate transfer of the cells to 4°C and washing with ice-cold FACS buffer (PBS supplemented with 0.01% NaN3, 0.5% BSA, and 0.35 mM EDTA). Cells were treated with vital blue stain (Orpegen) to quench extracellular fluorescence, labeled with Gr1-PE (BD Pharmingen), washed with FACS buffer, and analyzed using a flow cytometer (FACSCalibur; BD Biosciences). Neutrophils were gated based on forward scatter and Gr1 positivity. Results are expressed as phagocytosis index, defined as: (mean fluorescence x percent positive cells at 37°C) minus (mean fluorescence x percent positive cells at 4°C). To determine whether there is a difference in the adherence of heat-killed P. aeruginosa to the Wt and PAFR–/– neutrophils, we repeated this assay with and without quenching in one separate experiment.
Bacterial killing of P. aeruginosa
Bacterial killing was determined according to a protocol published recently (30, 31). Peritoneal lavage was performed in Wt and PAFR–/– mice (n = 7) using 5 ml of sterile saline. Lavage fluid was collected in sterile tubes and put on ice. Peritoneal macrophages were washed, counted, and resuspended in RPMI 1640 with L-glutamine at a final concentration of 0.2 x 106/ml. Cells were then allowed to adhere in 12-well microtiter plates (Greiner) overnight at 37°C. Adherent monolayer cells were washed thoroughly with RPMI 1640 with L-glutamine. P. aeruginosa were added at a multiplicity of infection of 500 and spun onto cells at 2000 rpm for 5 min., after which plates were placed at 37°C for 10 min. Each well was then washed five times with ice-cold PBS to remove extracellular bacteria. To determine bacterial uptake after 10 min., wells were lysed with sterile H2O and designated as t = 0. Prewarmed RPMI 1640 with L-glutamine was added to the remaining cells and plates were placed at 37°C for 5 and 30 min, after which the cells were again washed five times with ice-cold PBS and lysed as described before. Cell lysates were plated in serial-fold dilutions on blood agar plates and bacterial counts were enumerated after 16 h. Bacterial killing was expressed as the percentage of killed bacteria in relation to t = 0 (percent killing = 100 – {(No. of CFUs at time x/No. of CFUs at time 0) x 100}).
Cell counts and differentials
Cell counts were determined in BALF using an automated counter (Coulter ZF; Beckman Coulter). Subsequently, BALF was centrifuged and supernatant was stored at –20°C until further assayed; the pellet was suspended in PBS until a final concentration of 105 cells/ml and differential cell counts were performed on cytospin Giemsa stain (Diff-Quick; Dade Behring).
Histological examination
Lungs, livers, and spleens for histologic examination were harvested after 6 h, fixed in 4% formaldehyde, and embedded in paraffin. Four-micrometer-thick sections were stained with H&E and analyzed by a pathologist who had no knowledge of the genotype of the mice. To score lung inflammation and damage, the lung samples were screened for the following parameters: interstitial inflammation, endothelialitis, bronchitis, edema, and pleuritis. Each parameter was graded on a scale of 0–5 (0, absent; 1, very mild; 2, mild; 3, moderate; 4, severe; and 5, very severe). The total histology score was expressed as the (mean) sum of the score for all parameters. Neutrophil stainings were performed as described previously (32). Neutrophil infiltration was analyzed (blinded) in four nonoverlapping areas in each specimen and graded on a scale of 0–5 as described above. The mean neutrophil staining score was expressed as the mean score of four areas. Fibrin(ogen) stainings were performed as earlier described (25, 33). Surface areas immunostained with fibrin(ogen) were analyzed in a blinded fashion using image analysis software. Of each specimen, digital images were captured of three nonoverlapping areas (x20 objective) using a DFC500 digital camera mounted on a DM5000B microscope (both from Leica Microsystems). The area positive for fibrin(ogen) was determined with Image Pro Plus (Media Cybernetics) and expressed as the percentage of the total surface area.
Assays
TNF-
, IL-6, MCP-1, and IL-10 levels were determined using a cytometric beads array (CBA) multiplex assay (BD Biosciences) in accordance with the manufacturers recommendations. Keratinocyte-derived chemokine (KC) and MIP-2 levels were measured by ELISA (R&D Systems) according to the manufacturers instructions. Myeloperoxidase (MPO) was measured by ELISA (Hycult Biotechnology). Protein levels in BALF were measured using the bicinchoninic acid protein kit (Pierce) with BSA as a standard. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined with commercially available kits (Sigma-Aldrich) using a Hittachi analyzer (Boehringer Mannheim). Thrombin-antithrombin complexes (TATc) were measured by ELISA (Enzygnost TAT Micro). D-dimer was quantitated by a sandwich-type ELISA (Asserachrom D-dimer; Diagnostica Stago).
Ex vivo alveolar macrophages stimulation
Alveolar macrophages were harvested from Wt and PAFR–/– mice by bronchoalveolar lavage as previously described (26, 27). Total cell numbers were counted from each BALF sample using a hemocytometer. Cells were washed and resuspended in RPMI 1640 containing 1 mM pyruvate, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen Life Technologies) in a final concentration of 1 x 105 cells/ml. Cells were then cultured in 96-well microtiter plates (Greiner) for 24 h and washed with RPMI 1640 to remove nonadherent cells. Adherent monolayer cells were stimulated with LPS from P. aeruginosa, 0.1 or 1 µg/ml (Sigma-Aldrich), or RPMI 1640 (control) for 24 h. Supernatants were collected and stored at –20°C until assayed for TNF-
and KC.
Statistical analysis
All data are expressed as means ± SEM. Differences between groups were analyzed by Mann-Whitney U test. Values of p < 0.05 were considered to represent a statistically significant difference.
| Results |
|---|
|
|
|---|
To obtain insight in the role of PAFR in host defense against respiratory tract infection by P. aeruginosa, we intranasally infected PAFR–/– and Wt mice with Pseudomonas (108 CFUs) and determined the pulmonary bacterial loads 6 h after inoculation. PAFR–/– mice had significantly higher bacterial loads in their lung homogenates and BALF than Wt mice (p < 0.05; Fig. 1, A and B). In addition, blood, liver, and spleen homogenates harvested from PAFR–/– mice also contained more bacteria when compared with the corresponding body samples from Wt mice (all p < 0.05; Fig. 1, C–E). Thus, PAFR–/– mice showed a clearly increased outgrowth of P. aeruginosa at the primary site of infection which was accompanied by an enhanced dissemination of the bacteria. To obtain further proof of a beneficial role for PAFR in host defense against Pseudomonas pneumonia, we inoculated Wt and PAFR–/– mice with a 10-fold lower inoculum (107 CFUs). This bacterial dose caused a relatively mild pneumonia without bacterial dissemination to blood or distant organs (data not shown). In accordance with the results obtained with the higher inoculum, PAFR–/– mice displayed significantly higher bacterial loads in their lungs than Wt mice (p < 0.05, Fig. 2).
|
|
The increased bacterial load in PAFR–/– mice could be caused by an intrinsic defect of PAFR–/– cells to phagocytose P. aeruginosa. To investigate this possibility, we harvested whole blood from uninfected Wt and PAFR–/– mice and compared the capacity of neutrophils to phagocytose FITC-labeled P. aeruginosa. PAFR–/– neutrophils displayed a decreased ability to phagocytose P. aeruginosa (Fig. 3A). Quenching, which removes Pseudomonas from the cell surface, had little if any effect on the FACS signal in either Wt or PAFR–/– cells, suggesting that the vast majority of bacteria were intracellular (data not shown). To investigate whether this reduced phagocytosis capacity could explain the observed enhanced bacterial outgrowth in the PAFR–/– mice, we performed a killing assay using live P. aeruginosa. In line with the phagocytosis data, killing of viable P. aeruginosa by PAFR–/– cells was diminished (Fig. 3B).
|
To evaluate the role of endogenous PAFR in lung inflammation and injury during P. aeruginosa pneumonia, we analyzed lung tissue slides obtained from PAFR–/– and Wt mice 6 h after inoculation. Upon histopathologic examination, the lungs of Wt mice showed interstitial inflammation along with endothelialitis, bronchitis, edema, and pleuritis (Fig. 4A). Lung inflammation (e.g., interstitial inflammation, edema) in PAFR–/– mice (Fig. 4B) was more profound compared with that in Wt mice. The mean total histology score of the lungs (determined using the scoring system described in Materials and Methods) was significantly higher in PAFR–/– mice than in Wt mice (p < 0.01; Fig. 4C). In line, PAFR–/– mice had an increased relative lung weight (p < 0.05; Fig. 4D). Furthermore, the extent of lung injury was determined by total protein concentrations in BALF (reflecting lung leakage and/or exudate formation), which were elevated in PAFR–/– mice compared with Wt mice (p < 0.05; Fig. 4E). In conclusion, PAFR–/– mice showed more lung inflammation and damage.
|
Having shown that PAFR contributes to containment of the infection within the lungs, we then asked ourselves which factors might be involved in the early spread of P. aeruginosa. Given that leukocyte recruitment to the site of infection is an important part of host defense during pneumonia (34, 35), we next investigated neutrophil influx in the lungs of Wt and PAFR–/– mice 6 h after inoculation. PAFR–/– mice had an increased influx of neutrophils in the lungs compared with the Wt mice, as reflected by neutrophil stainings of lung tissue (Fig. 5, A and B). The granulocyte Ly-6 scores of the lungs (semiquantified according to the scoring system described in Materials and Methods) were significantly higher in PAFR–/– mice than in Wt mice (p < 0.05; Fig. 5C). In line, PAFR–/– mice had higher MPO levels in their lung homogenates (p < 0.01; Fig. 5D). Remarkably, cell influx in the bronchoalveolar space was unaffected, reflected by similar total leukocyte counts (Fig. 5E) and similar neutrophil influx (Fig. 5F) in BALF of Wt and PAFR–/– mice. These data indicate that PAFR deficiency is associated with enhanced neutrophil recruitment to the lung interstitium.
|
CXC chemokines have been implicated in the attraction of neutrophils to the site of an infection (36, 37). To investigate whether a difference in local chemokine levels could have influenced the neutrophil influx in the interstitial lung tissue and bronchoalveolar space, we determined KC and MIP-2 levels in lung homogenates and BALF 6 h after P. aeruginosa inoculation in Wt and PAFR–/– knockout mice. PAFR–/– mice showed significantly lower levels of KC in their lung homogenates and BALF than Wt mice (both p < 0.05; Fig. 6, A and B), suggesting that elevated levels of the neutrophil-attracting chemokine KC is a less probable explanation of the increased neutrophil influx in the lung interstitium in PAFR–/– mice. MIP-2 levels were increased in lung homogenates of the PAFR–/– mice compared with Wt mice (Fig. 6C), while MIP-2 BALF concentrations were similar in both genotypes (Fig. 6D).
|
To investigate whether PAFR deficiency influences the local or systemic cytokine response to P. aeruginosa, pro- and anti-inflammatory cytokines were measured in lung homogenates and plasma at 6 h after inoculation (Table I). In lung homogenates, IL-6, IL-10, and TNF-
levels were elevated in PAFR–/– mice (IL-6, IL-10; p < 0.01, TNF-
; p = 0.08 vs Wt mice). In addition, in plasma all cytokine levels were increased in the PAFR–/– mice (IL-6, MCP-1, and IL-10; p < 0.05, TNF-
; p = 0.08 vs Wt mice).
|
and less KC in their supernatants upon stimulation with P. aeruginosa LPS in vitro
Remarkably, PAFR–/– mice displayed lower KC and higher TNF-
levels in their lungs after infection with Pseudomonas. To determine the capacity of PAFR–/– alveolar macrophages to release these mediators, we harvested primary alveolar macrophages from PAFR–/– and Wt mice and stimulated these with LPS from P. aeruginosa. Supernatants from PAFR–/– macrophages contained more TNF-
(p < 0.05; Fig. 7A) and less KC (p < 0.005; Fig. 7B) upon stimulation with Pseudomonas LPS than those of Wt alveolar macrophages.
|
Pulmonary coagulopathy is an important feature of pneumonia (38, 39). To establish whether this model is associated with activation of the coagulation system, we performed fibrin(ogen) stainings on lung tissue slides (semiquantified to the scoring system described in Materials and Methods) and measured TATc and D-dimer levels in BALF and in plasma 6 h after intranasal inoculation of P. aeruginosa. Both PAFR–/– and Wt mice displayed strong evidence for local and systemic activation of coagulation: relative to uninfected mice, lungs of both mouse strains revealed markedly more fibrin(ogen) depositions (Fig. 8, A–D) and strongly elevated TATc (Fig. 8, E and G) and D-dimer (Fig. 8, F and H) concentrations in BALF and plasma. Importantly, coagulation activation was more profound in PAFR–/– mice, as reflected by enhanced fibrin(ogen) deposition and higher BALF and plasma TATc and D-dimer levels (all p
0.05 vs Wt mice, except for fibrin(ogen) staining, p = 0.06 and BALF D-dimer levels, p = 0.05 vs Wt mice; Fig. 8, B–H). Together, these data indicate that PAFR deficiency enhances the activation of coagulation and fibrinolysis both locally and systemically during P. aeruginosa pneumonia.
|
To determine whether this model results in hepatocellular injury, we measured plasma levels of AST and ALT 6 h after P. aeruginosa inoculation. Plasma AST and ALT were significantly increased in both PAFR–/– and Wt mice when compared with healthy control mice (Fig. 9). Both AST and ALT concentrations were higher in PAFR–/– mice, although for ALT the difference between the two genotypes did not reach statistical significance. (AST, p < 0.05, Fig. 9A, and ALT, p = 0.08, Fig. 9B). Of note, the hepatic parenchyma was unremarkable upon histopathological examination (data not shown).
|
Finally, to determine the impact of PAFR deficiency on the late host response to P. aeruginosa pneumonia, Wt and PAFR–/– mice were infected with 108 CFUs and killed 24 h later. At this time point, pulmonary bacterial loads had decreased in both mouse strains and were not different between groups anymore (Fig. 10A). Nonetheless, the differences between Wt and PAFR–/– mice with regard to the inflammatory response were in line with the results obtained 6 h after infection. In particular, PAFR–/– mice demonstrated more extensive lung inflammation as determined by histopathology, neutrophil influx in lung interstitium, and relative lung weight (Fig. 10, B–F). In addition, like after 6 h, lung KC levels were lower in PAFR–/– mice, whereas MIP-2 lung concentrations were higher (both p < 0.05 vs Wt mice; data not shown). Pulmonary cytokine levels were similar in both mouse strains (data not shown). PAFR deficiency did not influence mortality (Fig. 10G).
|
| Discussion |
|---|
|
|
|---|
Pneumonia caused by P. aeruginosa is characterized by the recruitment of phagocytic cells, especially neutrophils, to the site of infection (40, 41, 42). In our study, neutrophil influx into the lung interstitium was increased in the PAFR–/– mice 6 h after P. aeruginosa administration. A possible explanation for the increased pulmonary neutrophil influx in PAFR–/– mice is that it was the consequence of the increased proinflammatory stimulus provided by the higher bacterial load. In addition, the elevated local concentrations of the CXC chemokine MIP-2, which is known to contribute to neutrophil attraction to sites of the bacterial infection (36, 37), may have contributed. Remarkably, MIP-2 levels in BALF of PAFR–/– mice were not increased, whereas lung and BALF concentrations of KC, another CXC chemokine contributing to neutrophil recruitment (36, 37), were lower in the PAFR–/– mice. The finding of reduced KC levels in the presence of a higher bacterial burden can at least in part be explained by a diminished capacity of PAFR–/– alveolar macrophages to release this chemokine upon stimulation with Pseudomonas LPS. Earlier, it was described that the administration of a PAFR antagonist inhibited the increase of KC lung levels in mice injected with a venom (43), which is in line with our study. The observation that the neutrophil influx and vascular permeability in the venom model were also decreased in the mice in which PAFR was blocked, while these (and other) parameters were increased in our Pseudomonas model, could be due to higher bacterial load in our model. However, it is interesting that KC levels in the PAFR–/– mice were consistently lower, while MIP-2 and cytokine levels were higher, suggesting a more specific relation between PAFR and KC release/degradation. Additional experiments are needed to investigate whether PAFR is important for KC release and signaling and whether this is pathogen (or stimulus) specific. Together, the higher bacterial load (either directly of more indirectly via MIP-2 in lung homogenate) could have contributed to the increased neutrophil influx in the lung interstitium in PAFR–/– mice, but additional chemokine-independent effects on cell recruitment seem more likely. Despite the increase in the neutrophil influx, the clearance of P. aeruginosa was diminished in the PAFR–/– mice. One could speculate that this might be due to a decreased activation of the neutrophils of the PAFR–/– mice. Previously, Au et al. (44) found that pretreatment with a PAFR antagonist blocked the increase in the expression of the activation-dependent epitope on CD11/CD18 in human neutrophils stimulated with zymosan.
Moreno et al. (45) showed that blockade of PAFR signaling was associated with an enhancement of neutrophil migration to the infectious site in a model of polymicrobial sepsis, which is in line with our findings. Because in their study PAFR blockade was associated with decreased bacterial outgrowth, the increased neutrophil migration to the peritoneal cavity during PAFR blockade was unlikely to be the consequence of a higher bacterial load. Moreover, Moreno et al. (45) showed in an ex vivo experiment that PAFR blockade increased the rolling and adhesion of neutrophils on endothelial cells harvested 4 h after induction of sepsis. Additional experiments are needed to investigate whether PAFR blockade enhances neutrophil rolling and adhesion during P. aeruginosa pneumonia.
In our P. aeruginosa pneumonia model, PAFR–/– mice had higher levels of cytokines in their lung homogenates, BALF, and plasma compared with Wt mice 6 h after infection. These differences could in part be due to the increased bacterial load in the PAFR–/– mice. However, an (additional) intrinsic effect is very well possible, because we found that in vitro stimulation with LPS from P. aeruginosa led to more TNF-
in supernatants of alveolar macrophages from PAFR–/– mice compared with Wt mice. In addition, Soares et al. (10) showed that the concentrations of TNF-
in BALF from PAFR–/– mice were diminished after K. pneumoniae infection, suggesting a more (pathogen) specific effect from (LPS from) P. aeruginosa on PAFR–/– cells. Therefore, the increased cytokine levels in the PAFR–/– mice in our P. aeruginosa model could partially be explained by a higher bacterial load and by an intrinsic effect of (LPS from) P. aeruginosa on cells deficient in PAFR.
Earlier it has been demonstrated that pulmonary coagulopathy is an important feature of pulmonary infection (38, 39), with changes in fibrin generation being restricted to the site of infection in patients with community-acquired pneumonia caused by S. pneumoniae (46) or ventilator-associated pneumonia caused by several pathogens, among others P. aeruginosa (47, 48). Pulmonary coagulopathy now gains more and more interest as a new target in therapeutic studies of acute lung injury of pneumonia (49, 50, 51). PAF can mediate procoagulant activity on the surface of endothelial cells possibly partly via PAFR (51). Moreover, Yokota et al. (52) showed with an in vivo study that administration of a PAFR antagonist inhibits LPS-induced disseminated intravascular coagulation in rats. To determine whether our P. aeruginosa model is associated with activation of the coagulation system locally and systemically, we measured TAT-c and D-dimer levels in the bronchoalveolar space and plasma and performed fibrin(ogen) lung stainings. TATc as well as D-dimer levels were increased in BALF and plasma 6 h after P. aeruginosa inoculation compared with healthy mice. In line, there was more fibrin deposition in the lungs of the mice with P. aeruginosa pneumonia. PAFR deficiency enhanced all of these procoagulant phenomena, indicating that PAFR is not essential for coagulation activation during Pseudomonas pneumonia. In this context, it is important to emphasize that PAFR signaling plays an eminent role in lung injury caused by sterile inflammatory stimuli (11, 12, 13). In our pneumonia model, the higher bacterial loads might have overruled this effect of PAFR deficiency, resulting in net increased lung inflammation and damage in the lungs of PAFR–/– mice compared with that of the Wt mice. Our study indicates that the increased bacterial loads in the PAFR–/– mice can at least in part be explained by a reduced capacity of PAFR–/– neutrophils to phagocytose Pseudomonas. In line, results from other in vitro investigations suggest a role of PAF and its receptor during phagocytosis of different pathogens (8, 9).
Although PAFR deficiency was associated with higher bacterial loads early (6 h) after inoculation, later during the course of the infection (24 h) both mouse strains appeared capable of partially clearing the infection as demonstrated by similar bacterial loads in lungs at this time point. Nonetheless, PAFR–/– mice still demonstrated evidence of increased lung inflammation. PAFR deficiency did not influence mortality. In this respect, it should be noted that the mortality curves after infection of previously healthy mice with this Pseudomonas strain are very steep: whereas low doses do not cause lethality, doses that do cause lethality almost invariably do so. Hence, we consider this model less suitable to determine the impact on mortality and rather make use of it to study early host defense mechanisms (21, 24).
Several earlier studies investigated the role of PAFR in bacterial pneumonia. Our laboratory reported on the impact of PAFR deficiency in respiratory tract infection caused by pathogens that express phosphorylcholine (a ligand for PAFR) in their cell wall (17, 18, 19). These studies revealed that S. pneumoniae uses PAFR to cause invasive infection (17, 18), whereas this receptor does not play a role of importance during H. influenzae pneumonia (19). In addition, Soares et al. (10) demonstrated that PAFR deficiency impairs host defense against Klebsiella pneumoniae pneumonia, resulting in higher bacterial loads during the course of the infection. The current study is the first to establish that PAFR is important for antibacterial defense against Pseudomonas pneumonia. Moreover, our results extensively document the fact that PAFR is not essential for the induction of excessive lung inflammation and injury. Indeed, the increased bacterial loads in PAFR–/– mice were associated with exaggerated inflammation, coagulation, and injury despite the absence of PAFR-mediated signaling. These data further illustrate the existence of a delicate balance between inflammation and anti-inflammation, in which a certain degree of inflammation is required to combat invading pathogens and exaggerated inflammation can result in severe tissue injury.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was performed at the Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ![]()
2 Address correspondence and reprint requests to Dr. Marieke A. D. van Zoelen, Academic Medical Center, Room G2-130, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. E-mail address: M.A.vanZoelen{at}amc.uva.nl ![]()
3 Abbreviations used in this paper: PAF, platelet-activating factor; PAFR, PAF receptor; Wt, wild type; BALF, bronchoalveolar lavage fluid; MPO, myeloperoxidase; KC, keratinocyte-derived chemokine; TATc, thrombin-anithrombin complex. ![]()
Received for publication April 24, 2007. Accepted for publication December 27, 2007.
| References |
|---|
|
|
|---|
in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect. Immun. 63: 3272-3278. [Abstract]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |